Iovance Biotherapeutics: Q4 Earnings Snapshot

Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why

Quick Read Iovance Biotherapeutics (IOVA) reported Q4 revenue of $86.71M. Gross margin expanded to 50% from 38.2%. Iovance’s internalized Philadelphia facility supports 5,000 patients annually with 32-day turnaround times. FDA Fast Track for NSCLC addresses a market seven times larger than melanoma. Finally! You can open a SoFi Crypto account and access 25 plus cryptocurrencies without juggling apps or logins. A relative unknown, if you don’…

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy - Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas. This news has energized investors as the broader market is experiencing gains, with the Nasdaq up 0.51%. Among the first six evaluable patients treated with lifileucel monotherapy, the trial showed a 50% confirmed objective response rate (ORR).…

Iovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Beats Expectations By $0.04 EPS

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 158.78% and a negative return on equity of 55.24%. The firm had revenue of $86.71 million for the quarter, compared to analyst estimates of $81.61 million.

Iovance Biotherapeutics: Q4 Earnings Snapshot

SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Tuesday reported a loss of $71.9 million in its fourth quarter. On a per-share basis, the San Carlos, California-based company said it had a loss of 18 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 22 cents per share. The biotechnology company posted revenu…

Stock Traders Buy High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Traders purchased 27,681 call options on the stock. This represents an increase of 364% compared to the average daily volume of 5,961 call options. Institutional Inflows and Outflows A number of institutional investors and hedge funds […]